Cargando…
Oncolytic Viruses: An Inventory of Shedding Data from Clinical Trials and Elements for the Environmental Risk Assessment
Attenuated and/or genetically modified oncolytic viruses (OV) gain increasing interest as a promising approach for cancer therapy. Beside the assessment of subject safety, quality and efficacy aspects of medicinal products for human use, genetically modified viruses are also governed by EU regulator...
Autores principales: | Onnockx, Sheela, Baldo, Aline, Pauwels, Katia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535390/ https://www.ncbi.nlm.nih.gov/pubmed/37766125 http://dx.doi.org/10.3390/vaccines11091448 |
Ejemplares similares
-
Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2
por: Baldo, Aline, et al.
Publicado: (2021) -
Recommendations for Regulating the Environmental Risk of Shedding for Gene Therapy and Oncolytic Viruses in Canada
por: Bubela, Tania, et al.
Publicado: (2019) -
A clinical trial investigating biodistribution and shedding of an oncolytic virus
por: Reale, Alberto, et al.
Publicado: (2019) -
Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors
por: Goossens, Martine, et al.
Publicado: (2013) -
Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
por: Andtbacka, Robert H.I., et al.
Publicado: (2019)